MCID: BPL003
MIFTS: 62

Bipolar Disorder malady

Categories: Rare diseases, Mental diseases, Genetic diseases

Aliases & Classifications for Bipolar Disorder

Aliases & Descriptions for Bipolar Disorder:

Name: Bipolar Disorder 38 12 50 24 25 52 41 42 14 69
Bipolar Affective Disorder 50 25
Manic-Depressive Psychosis 50 24
Major Affective Disorder 50 69
Depression, Bipolar 25 69
Manic Depression 12 50
Manic Disorder 12 69
Manic Bipolar Affective Disorder 12
Bipolar Disorder Manic Phase 12
Bipolar Affective Psychosis 25
Major Affective Disorder 1 69
Major Affective Disorder 2 69
Manic Depressive Disorder 12
Bipolar Spectrum Disorder 25
Manic Bipolar I Disorder 12
Manic Depressive Illness 25
Affective Disorder Major 52
Depressive-Manic Psych. 12
Bipolar Disorder, Mixed 69
Mixed Bipolar Disorder 12
Bipolar Depression 12
Depression Bipolar 52
Bipolar Illness 50

Classifications:



Summaries for Bipolar Disorder

MedlinePlus : 41 bipolar disorder is a serious mental illness. people who have it go through unusual mood changes. they go from very happy, "up," and active to very sad and hopeless, "down," and inactive, and then back again. they often have normal moods in between. the up feeling is called mania. the down feeling is depression. the causes of bipolar disorder aren't always clear. it runs in families. abnormal brain structure and function may also play a role. bipolar disorder often starts in a person's late teen or early adult years. but children and adults can have bipolar disorder too. the illness usually lasts a lifetime. if you think you may have it, tell your health care provider. a medical checkup can rule out other illnesses that might cause your mood changes. if not treated, bipolar disorder can lead to damaged relationships, poor job or school performance, and even suicide. however, there are effective treatments to control symptoms: medicine and talk therapy. a combination usually works best. nih: national institute of mental health

MalaCards based summary : Bipolar Disorder, also known as bipolar affective disorder, is related to schizophrenia and personality disorder. An important gene associated with Bipolar Disorder is IMPA1 (Inositol Monophosphatase 1), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Aripiprazole and Fluoxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and eye, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and behavior/neurological

Disease Ontology : 12 A mood disorder that involves alternating periods of mania and depression.

Genetics Home Reference : 25 Bipolar disorder is a mental health condition that causes extreme shifts in mood, energy, and behavior. This disorder most often appears in late adolescence or early adulthood, although symptoms can begin at any time of life.

NIH Rare Diseases : 50 bipolar disorder is a type of mental illness that causes unusual shifts in mood, energy, activity levels, sleep and behavior. signs and symptoms typically include alternating periods of manic episodes (joyful or excited states) and depressive episodes (very sad, hopeless or empty states). mood episodes may also include symptoms of both mania and depression (a mixed state). it often develops in the late teens or early adult years, but age of onset can range from childhood to late in life. bipolar disorder can run in families, although no single gene is thought to cause the condition. many factors acting together likely increase a person's risk to develop the disorder. treatment may include medication and psychotherapy for preventing relapses and reducing the severity of symptoms. last updated: 11/18/2011

Wikipedia : 71 Bipolar disorder, also known as manic depression, is a mental disorder that causes periods of depression... more...

Related Diseases for Bipolar Disorder

Diseases in the Bipolar Disorder family:

Bipolar Ll Disorder Bipolar I Disorder

Diseases related to Bipolar Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 188)
id Related Disease Score Top Affiliating Genes
1 schizophrenia 31.3 BDNF DAOA DISC1 DRD3 GAD1 GNAL
2 personality disorder 30.2 BDNF DISC1 DRD3 GAD1 HTR2A NRG1
3 bipolar i disorder 11.2
4 mood disorder 11.1
5 major depressive disorder and accelerated response to antidepressant drug treatment 11.1
6 psychotic disorder 11.0
7 darier disease 11.0
8 major affective disorder 1 10.9
9 major affective disorder-7 10.9
10 cyclothymic disorder 10.8
11 schizophrenia 15 10.7
12 mental retardation, x-linked, syndromic 13 10.7
13 schizophrenia susceptibility 18 10.7
14 bipolar ll disorder 10.7
15 chromosome 15q13.3 microdeletion syndrome 10.7
16 valproate embryopathy, susceptibility to 10.7
17 schizophrenia 17 10.7
18 schizophrenia 4 10.7
19 carotid stenosis 10.3 SLC6A3 SLC6A4 TPH1
20 cholesteatoma 10.3 BDNF SLC6A3 SLC6A4
21 intrahepatic gall duct cancer 10.3 BDNF HTR2A SLC6A4
22 splenic abscess 10.3 HTR2A SLC6A3 SLC6A4
23 transmitted_by 10.3 DRD3 SLC6A3 SLC6A4
24 chondrodysplasia lethal recessive 10.3 DAOA GAD1 NRG1 TPH1
25 mucinous adenocarcinoma 10.3 BDNF DRD3 SLC6A3 SLC6A4
26 primary angle-closure glaucoma 10.3 BDNF HTR2A NRG1 SLC6A4
27 hypereosinophilic syndrome 10.3 BDNF DRD3 SLC6A3 SLC6A4
28 hypoglycemic coma 10.3 BDNF HTR2A SLC6A4 TPH1
29 multiple personality disorder 10.3 BDNF HTR2A SLC6A4 TPH1
30 teratoma with malignant transformation 10.3 BDNF DRD3 HTR2A
31 hypoglycemia 10.3 BDNF DRD3 SLC6A4
32 postencephalitic parkinson disease 10.3 BDNF HTR2A SLC6A4 TPH1
33 keratosis 10.3 BDNF HTR2A SLC6A4 TPH1
34 mitochondrial dna depletion syndrome 3 10.3 SLC6A3 TH TPH1
35 chagas disease 10.3 BDNF HTR2A SLC6A4
36 pyromania 10.3 DRD3 HTR2A SLC6A3 SLC6A4
37 hereditary multiple exostoses 10.3 BDNF HTR2A SLC6A4
38 alopecia 10.3 BDNF DRD3 SLC6A4
39 alzheimer disease 17 10.3 DRD3 HTR2A SLC6A4 TPH1
40 hepatitis d 10.2 BDNF HTR2A SLC6A3 SLC6A4 TPH1
41 ovarian mucinous adenocarcinoma 10.2 BDNF SLC6A3 TH
42 hemochromatosis, type 2a 10.2 BDNF DRD3 SLC6A3 TH
43 cecal benign neoplasm 10.2 DRD3 HTR2A SLC6A3 SLC6A4 TPH1
44 suppurative periapical periodontitis 10.2 CREB1 DRD3 TH
45 sexual disorder 10.2 BDNF RELN SLC6A4
46 cytomegalic congenital adrenal hypoplasia 10.2 BDNF DRD3 HTR2A SLC6A4 TH
47 retinoblastoma 10.2 BDNF DRD3 HTR2A SLC6A3 SLC6A4 TPH1
48 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 10.2 BDNF HTR2A SLC6A4
49 epithelioid type angiomyolipoma 10.2 BDNF HTR2A SLC6A3 SLC6A4 TH
50 atrial fibrillation, familial, 10 10.2 BDNF HTR2A SLC6A4 TH TPH1

Comorbidity relations with Bipolar Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Diabetes Insipidus, Nephrogenic
Hypertension, Essential Hypothyroidism
Major Affective Disorder-7 Parkinson Disease, Late-Onset
Schizophrenia Schizophreniform Disorder
Tardive Dyskinesia

Graphical network of the top 20 diseases related to Bipolar Disorder:



Diseases related to Bipolar Disorder

Symptoms & Phenotypes for Bipolar Disorder

GenomeRNAi Phenotypes related to Bipolar Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.58 IMPA2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.58 IMPA2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.58 GSK3B
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.58 PDLIM5 GSK3B IMPA2 NRG1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.58 GSK3B
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.58 IMPA2 NRG1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 9.58 NRG1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.58 NRG1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.58 NRG1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.58 IMPA2
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.58 NRG1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.58 IMPA2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.58 GSK3B
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-98 9.58 GSK3B

MGI Mouse Phenotypes related to Bipolar Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 XBP1 BDNF CREB1 DISC1 DRD3 GAD1
2 growth/size/body region MP:0005378 10.13 BDNF CREB1 DISC1 DRD3 GAD1 GNAL
3 mortality/aging MP:0010768 10.1 BDNF CREB1 DRD3 GAD1 GNAL GSK3B
4 endocrine/exocrine gland MP:0005379 10.02 BDNF CREB1 GAD1 GSK3B HTR2A SLC6A3
5 digestive/alimentary MP:0005381 9.95 BDNF DRD3 GAD1 GSK3B HTR2A RELN
6 nervous system MP:0003631 9.83 BDNF CREB1 DISC1 DRD3 GAD1 GSK3B
7 muscle MP:0005369 9.76 CREB1 HTR2A PDLIM5 RELN SLC6A3 SLC6A4
8 taste/olfaction MP:0005394 8.92 BDNF GAD1 GNAL SLC6A3

Drugs & Therapeutics for Bipolar Disorder

Drugs for Bipolar Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 522)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
2
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 54910-89-3 3386
3
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
4
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 113-45-1 4158
5
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 132539-06-1 4585
6
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 106266-06-2 5073
7
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1 79617-96-2 68617
8
Topiramate Approved Phase 4,Phase 3,Phase 1 97240-79-4 5284627
9
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
10
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
11
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 298-46-4 2554
12
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
13
Acamprosate Approved, Investigational Phase 4,Phase 1,Phase 2 77337-76-9 71158
14
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
15
Coal tar Approved Phase 4,Phase 2 8007-45-2
16
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
17
Oxcarbazepine Approved Phase 4,Phase 2,Phase 3 28721-07-5 34312
18
Bupropion Approved Phase 4,Phase 3,Phase 1,Phase 2 34841-39-9, 34911-55-2 444
19
Tranylcypromine Approved Phase 4 155-09-9 441233
20
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
21
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1 59729-33-8 2771
22
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 61869-08-7 43815
23
Benzocaine Approved Phase 4,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
24
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 6740-88-1 3821
25
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
26
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
27
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2 112111-43-0
28
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2 68693-11-8 4236
29
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
30
Memantine Approved, Investigational Phase 4,Phase 2,Phase 3 19982-08-2 4054
31
Nortriptyline Approved Phase 4 72-69-5 4543
32
Pramipexole Approved, Investigational Phase 4,Phase 2 104632-26-0 59868 119570
33
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 16590-41-3 5360515
34
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 1,Phase 2 50-36-2 5760 446220
35
Asenapine Approved Phase 4,Phase 3,Phase 2,Phase 1 85650-56-2, 65576-45-6 3001386
36
Galantamine Approved Phase 4,Phase 3 357-70-0 9651 908828, 9651
37
Clozapine Approved Phase 4,Phase 3,Phase 2 5786-21-0 2818
38
Allopurinol Approved Phase 4,Phase 3 315-30-0 2094
39
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
40
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
41
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
42
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
43
Acetylcholine Approved Phase 4 51-84-3 187
44
Cycloserine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 68-41-7 401 6234
45
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
46
Donepezil Approved Phase 4 120014-06-4 3152
47
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2 10118-90-8 5281021
48
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
49
Dipyridamole Approved Phase 4 58-32-2 3108
50 Piracetam Approved Phase 4,Phase 2 7491-74-9

Interventional clinical trials:

(show top 50) (show all 1469)
id Name Status NCT ID Phase
1 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4
2 Juvenile Bipolar Disorder Outpatient Program Unknown status NCT01000402 Phase 4
3 Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD) Unknown status NCT01272531 Phase 4
4 Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder Unknown status NCT00325286 Phase 4
5 Iloperidone in Mixed States of Bipolar Disorder Unknown status NCT02413918 Phase 4
6 Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder Unknown status NCT01543724 Phase 4
7 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4
8 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4
9 Acamprosate vs. Placebo in Bipolar Alcoholics Unknown status NCT00466661 Phase 4
10 Efficacy of N-Acetyl-Cysteine in Bipolar Disorder and Tobacco Use Disorder Unknown status NCT02252341 Phase 4
11 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4
12 Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified(OL Study) Unknown status NCT02287259 Phase 4
13 Algorithm Guided Treatment Strategies for Bipolar Depression Unknown status NCT01938859 Phase 4
14 Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4
15 Tranylcypromine Treatment of Bipolar Depression Unknown status NCT01430455 Phase 4
16 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4
17 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4
18 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4
19 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
20 Efficacy and Safety of Utapine vs. Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4
21 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
22 Neurophysiologic Changes in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4
23 Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients Unknown status NCT01710163 Phase 4
24 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4
25 Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4
26 Bipolar Sealer Aquamantys Use in Total Knee Replacement Unknown status NCT01736644 Phase 4
27 A Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia Unknown status NCT01218672 Phase 4
28 The Hysteroscopic Morcellator (HM). Unknown status NCT01537822 Phase 4
29 Effect of Human Thrombin With Gelatin Matrix on Perioperative Blood Loss in Scoliosis Surgery Unknown status NCT01451788 Phase 4
30 Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness Completed NCT00545675 Phase 4
31 Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder Completed NCT01010204 Phase 4
32 The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States. Completed NCT00154323 Phase 4
33 Memantine and Cognitive Dysfunction in Bipolar Disorder Completed NCT00586066 Phase 4
34 Safety And Efficacy Study Of Depakote ER To Treat Pediatric Bipolar Disorder Completed NCT00199966 Phase 4
35 Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder Completed NCT00667745 Phase 4
36 Aripiprazole in Late Life Bipolar Disorder Completed NCT00194038 Phase 4
37 Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder Completed NCT00227968 Phase 4
38 Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness Completed NCT00545142 Phase 4
39 Quetiapine for Bipolar Disorder and Alcohol Dependence Completed NCT00457197 Phase 4
40 Comparative Effectiveness Study for Bipolar Disorder Completed NCT01331304 Phase 4
41 Olanzapine Compared to Lamotrigine in the Prevention of Depressive Episode in the Patients With Bipolar Disorder Completed NCT01864551 Phase 4
42 Ziprasidone in Pediatric Bipolar Disorder Completed NCT00622739 Phase 4
43 Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder Completed NCT02456896 Phase 4
44 Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode Completed NCT02918097 Phase 4
45 Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine Completed NCT00394095 Phase 4
46 An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder Completed NCT00360126 Phase 4
47 Cognitive Enhancement in Bipolar Disorder Completed NCT00597896 Phase 4
48 Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder Completed NCT00672490 Phase 4
49 Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad) Completed NCT01293825 Phase 4
50 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4

Search NIH Clinical Center for Bipolar Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: bipolar disorder

Genetic Tests for Bipolar Disorder

Genetic tests related to Bipolar Disorder:

id Genetic test Affiliating Genes
1 Bipolar Disorder 24

Anatomical Context for Bipolar Disorder

MalaCards organs/tissues related to Bipolar Disorder:

39
Brain, Cortex, Eye, Prefrontal Cortex, Cingulate Cortex, Testes, Amygdala

Publications for Bipolar Disorder

Articles related to Bipolar Disorder:

(show top 50) (show all 1840)
id Title Authors Year
1
Peripheral zinc and neopterin concentrations are associated with mood severity in bipolar disorder in a gender-specific manner. ( 28528241 )
2017
2
Parental Reports of Prodromal Psychopathology in Pediatric Bipolar Disorder. ( 28503109 )
2017
3
Modifiable and non-modifiable factors associated with functional impairment during the inter-episodic periods of bipolar disorder. ( 28534186 )
2017
4
A prospective study of bipolar disorder vulnerability in relation to behavioural activation, behavioural inhibition and dysregulation of the Behavioural Activation System. ( 28535407 )
2017
5
Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter-observational study. ( 28517032 )
2017
6
Evidence for genetic heterogeneity between clinical subtypes of bipolar disorder. ( 28072414 )
2017
7
Book review: Bipolar disorder in youth - Presentation, treatment and neurobiology Strakowski Stephen M DelBello Melissa P Adler Caleb M (eds), Bipolar disorder in youth - Presentation, treatment and neurobiology . New York, NY : Oxford University Press , 2015 . ISBN 978-0199985357 ; 382 pp., US $95.00 . ( 28504042 )
2017
8
Insulin-like Growth Factor Binding Protein 2 in bipolar disorder: an expression study in peripheral tissues. ( 28090803 )
2017
9
Personality traits as an endophenotype in genetic studies on suicidality in bipolar disorder. ( 27573591 )
2017
10
Surgical Management of Obesity Among People with Schizophrenia and Bipolar Disorder: a Systematic Review of Outcomes and Recommendations for Future Research. ( 28508277 )
2017
11
Chronic obstructive pulmonary disease associated with increased risk of bipolar disorder. ( 28528563 )
2017
12
Physical Activity Modulates Common Neuroplasticity Substrates in Major Depressive and Bipolar Disorder. ( 28529805 )
2017
13
Bipolar Disorder With Mixed Features Associated With Primary Hyperparathyroidism. ( 28010754 )
2017
14
The effect of premorbid intelligence on neurocognitive and psychosocial functioning in bipolar disorder. ( 28063385 )
2017
15
Risk factors for early cardiovascular mortality in patients with bipolar disorder. ( 28523821 )
2017
16
Clinical Outcomes in Children and Adolescents With Bipolar Disorder and Substance Use Disorder Comorbidity. ( 28068464 )
2017
17
Is Toxoplasma gondii a Trigger of Bipolar Disorder? ( 28075410 )
2017
18
Free Interval Duration: Clinical Evidence of the Primary Role of Excitement in Bipolar Disorder. ( 28503111 )
2017
19
The Role of Electroconvulsive Therapy (ECT) in Bipolar Disorder: Effectiveness in 522 Patients with Bipolar Depression, Mixed-state, Mania and Catatonic Features. ( 28503107 )
2017
20
One-Year Developmental Outcomes for Infants of Mothers With Bipolar Disorder. ( 28068465 )
2017
21
Structural correlates of trait impulsivity in patients with bipolar disorder and healthy controls: a surface-based morphometry study. ( 28077175 )
2017
22
Diabetes mellitus and first episode mania associated with cardiovascular diseases in patients with older-age bipolar disorder. ( 28073032 )
2017
23
A meta-analysis of neurocognition in youth with familial high risk for bipolar disorder. ( 28531561 )
2017
24
Effects of glutathione S-transferase M1 andT1 deletions on bipolar disorder risk among a Tunisian population. ( 28043918 )
2017
25
Depression and Mania in Bipolar Disorder. ( 28503106 )
2017
26
Book Review: Finding Sanity John Cade, lithium and the taming of bipolar disorder de Moore Greg Westmore Ann . Allen and Unwin , Sydney. ( 28068832 )
2017
27
Cost-effectiveness of structured group psychoeducation versus unstructured group support for bipolar disorder: Results from a multi-centre pragmatic randomised controlled trial. ( 28086146 )
2017
28
Risperidone Induced Granulomatous Mastitis Secondary to Hyperprolactinemia in a Non-Pregnant Woman-A Rare Case Report in a Bipolar Disorder. ( 28273980 )
2017
29
Use of an Analog Scale in the Treatment of Patients With Bipolar Disorder to Optimize Assessment and Clinical Outcome. ( 28072644 )
2017
30
Trichotillomania and Bipolar Disorder. ( 28142271 )
2017
31
Refining Treatment Approaches in Comorbid Trichotillomania and Bipolar Disorder: Response to Sharma and Baczynski. ( 28142278 )
2017
32
Shared abnormality of white matter integrity in schizophrenia and bipolar disorder: A comparative voxel-based meta-analysis. ( 28082140 )
2017
33
Differences in cognitive deficits in individuals with subthreshold syndromes with and without family history of bipolar disorder. ( 28521253 )
2017
34
Successful Treatment With Electroconvulsive Therapy of a Patient With Bipolar Disorder and a 7-mm Cerebral Aneurysm. ( 28072662 )
2017
35
Too Fast or Too Slow? Time and Neuronal Variability in Bipolar Disorder-A Combined Theoretical and Empirical Investigation. ( 28525601 )
2017
36
Lifetime presence of psychotic symptoms in bipolar disorder is associated with less favorable socio-demographic and certain clinical features. ( 28531646 )
2017
37
Association analysis of ANK3 variants with bipolar disorder in the Korean population. ( 28079488 )
2017
38
The association between insomnia-related sleep disruptions and cognitive dysfunction during the inter-episode phase of bipolar disorder. ( 28088728 )
2017
39
Residual depressive symptoms, sleep disturbance and perceived cognitive impairment as determinants of functioning in patients with bipolar disorder. ( 28068616 )
2017
40
Abnormalities in High-Energy Phosphate Metabolism in First-Episode Bipolar Disorder Measured Using (31)P-Magnetic Resonance Spectroscopy. ( 28527566 )
2017
41
Web-based integrated bipolar parenting intervention for parents with bipolar disorder: a randomised controlled pilot trial. ( 28512921 )
2017
42
Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants. ( 26475745 )
2016
43
TPH2 gene polymorphisms and bipolar disorder: A meta-analysis. ( 26365518 )
2016
44
A genetic variant in CAMKK2 gene is possibly associated with increased risk of bipolar disorder. ( 26354101 )
2016
45
A study of genetic and environmental contributions to structural brain changes over time in twins concordant and discordant for bipolar disorder. ( 27218817 )
2016
46
Impulsivity is associated with blood pressure and waist circumference among adolescents with bipolar disorder. ( 27665535 )
2016
47
Adverse childhood life events and postpartum psychosis in bipolar disorder. ( 27420133 )
2016
48
Novel, primate-specific PDE10A isoform highlights gene expression complexity in human striatum with implications on the molecular pathology of bipolar disorder. ( 26905414 )
2016
49
Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid. ( 26876913 )
2016
50
Disinhibition of the extracellular-signal-regulated kinase restores the amplification of circadian rhythms by lithium in cells from bipolar disorder patients. ( 27216486 )
2016

Variations for Bipolar Disorder

Copy number variations for Bipolar Disorder from CNVD:

7 (show top 50) (show all 399)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13918 1 100964950 101093664 Deletion Bipolar disorder
2 13959 1 101777242 101789688 Copy number Bipolar disorder
3 14276 1 106411328 106634702 Copy number Bipolar disorder
4 15012 1 111824223 111936532 Deletion Bipolar disorder
5 15144 1 112987422 113369070 Deletion Bipolar disorder
6 15198 1 113388739 114043773 Deletion Bipolar disorder
7 15265 1 114105331 114260861 Deletion Bipolar disorder
8 15293 1 114379103 114611497 Deletion Bipolar disorder
9 15315 1 114627212 115118807 Deletion Bipolar disorder
10 17285 1 142400000 148000000 Deletion Bipolar disorder
11 17371 1 142600000 147000000 Copy number Bipolar disorder
12 17555 1 14341488 14762438 Deletion Bipolar disorder
13 18108 1 144093481 144503421 Deletion Bipolar disorder
14 21577 1 159722810 159884140 Copy number FCGR2A Bipolar disorder
15 21578 1 159722810 159884140 Copy number FCGR2C Bipolar disorder
16 21579 1 159722810 159884140 Copy number FCGR3A Bipolar disorder
17 21580 1 159722810 159884140 Copy number FCGR3B Bipolar disorder
18 21581 1 159722810 159884140 Copy number HSPA6 Bipolar disorder
19 24355 1 179082079 179207535 Deletion Bipolar disorder
20 27840 1 214001144 214182688 Deletion Bipolar disorder
21 30012 1 239069843 239226340 Deletion Bipolar disorder
22 30852 1 246404335 246667943 Deletion Bipolar disorder
23 30991 1 247034191 247138092 Deletion Bipolar disorder
24 31736 1 30336050 30952188 Deletion Bipolar disorder
25 34240 1 53925291 53984359 Copy number GLIS1 Bipolar disorder
26 35075 1 59854502 60323099 Deletion Bipolar disorder
27 35289 1 62052182 62289893 Deletion Bipolar disorder
28 35722 1 66557267 66646247 Copy number PDE4B Bipolar disorder
29 35951 1 696962 803181 Deletion Bipolar disorder
30 37047 1 84784450 84864145 Copy number CTBS Bipolar disorder
31 37048 1 84784450 84864145 Copy number SPATA1 Bipolar disorder
32 37147 1 85996510 86164671 Deletion Bipolar disorder
33 38265 10 10058972 10215130 Deletion Bipolar disorder
34 39159 10 111195021 111323778 Deletion Bipolar disorder
35 39762 10 119100000 135374737 Deletion Bipolar disorder
36 40469 10 128361479 128559816 Deletion Bipolar disorder
37 42381 10 32899498 33000799 Deletion Bipolar disorder
38 42648 10 37554667 37710375 Deletion Bipolar disorder
39 43112 10 44523027 44679489 Copy number Bipolar disorder
40 43587 10 47013328 47173619 Copy number Bipolar disorder
41 44374 10 56148428 56359760 Deletion Bipolar disorder
42 47196 10 90344868 90556337 Deletion Bipolar disorder
43 47223 10 90559662 90957411 Deletion Bipolar disorder
44 49063 11 102652001 102778728 Deletion Bipolar disorder
45 50159 11 114721884 114868905 Deletion Bipolar disorder
46 51811 11 131159857 131261275 Deletion Bipolar disorder
47 51869 11 132518807 132864395 Deletion Bipolar disorder
48 51963 11 133786141 134449982 Deletion Bipolar disorder
49 53165 11 25250128 26084796 Deletion Bipolar disorder
50 53245 11 26949271 27197653 Deletion Bipolar disorder

Expression for Bipolar Disorder

Search GEO for disease gene expression data for Bipolar Disorder.

Pathways for Bipolar Disorder

GO Terms for Bipolar Disorder

Cellular components related to Bipolar Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.65 GSK3B HTR2A KCNN3 SLC6A3 TH
2 cell body GO:0044297 9.5 DISC1 GSK3B NRG1
3 neuron projection GO:0043005 9.35 PDLIM5 SLC6A3 SLC6A4 TH TPH1
4 axon GO:0030424 9.17 CREB1 DISC1 GAD1 HTR2A NRG1 SLC6A3
5 cytoplasm GO:0005737 10.03 BDNF DISC1 GAD1 GSK3B HTR2A IMPA1

Biological processes related to Bipolar Disorder according to GeneCards Suite gene sharing:

(show all 28)
id Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol phosphorylation GO:0046854 9.8 IMPA1 IMPA2 NRG1
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.78 HTR2A NRG1 RELN
3 locomotory behavior GO:0007626 9.71 DRD3 NRG1 SLC6A3 TH
4 learning GO:0007612 9.7 DRD3 RELN TH
5 circadian rhythm GO:0007623 9.67 CREB1 GSK3B SLC6A4 TPH1
6 response to nicotine GO:0035094 9.65 CREB1 SLC6A3 TH
7 glial cell differentiation GO:0010001 9.64 NRG1 RELN
8 negative regulation of myotube differentiation GO:0010832 9.63 BDNF XBP1
9 cellular response to hepatocyte growth factor stimulus GO:0035729 9.62 CREB1 GSK3B
10 positive regulation of long-term synaptic potentiation GO:1900273 9.62 CREB1 RELN
11 memory GO:0007613 9.62 CREB1 HTR2A SLC6A4 TH
12 ammonium transmembrane transport GO:0072488 9.61 SLC6A3 SLC6A4
13 positive regulation of axon extension GO:0045773 9.61 DISC1 GSK3B NRG1
14 prepulse inhibition GO:0060134 9.6 DRD3 SLC6A3
15 dopamine biosynthetic process GO:0042416 9.59 SLC6A3 TH
16 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.58 DRD3 GNAL
17 positive regulation of cardiac muscle cell differentiation GO:2000727 9.58 GSK3B NRG1
18 inositol phosphate dephosphorylation GO:0046855 9.57 IMPA1 IMPA2
19 regulation of behavior GO:0050795 9.56 HTR2A RELN
20 social behavior GO:0035176 9.56 DRD3 GAD1 SLC6A4 TH
21 monoamine transport GO:0015844 9.55 SLC6A3 SLC6A4
22 aromatic amino acid family metabolic process GO:0009072 9.54 TH TPH1
23 inositol metabolic process GO:0006020 9.51 IMPA1 IMPA2
24 response to drug GO:0042493 9.5 CREB1 DRD3 GAD1 HTR2A SLC6A3 SLC6A4
25 dopamine uptake involved in synaptic transmission GO:0051583 9.49 SLC6A3 SLC6A4
26 inositol biosynthetic process GO:0006021 9.46 IMPA1 IMPA2
27 positive regulation of fat cell differentiation GO:0045600 9.46 CREB1 HTR2A TPH1 XBP1
28 neurotransmitter biosynthetic process GO:0042136 8.92 GAD1 SLC6A3 SLC6A4 TH

Molecular functions related to Bipolar Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein N-terminus binding GO:0047485 9.65 GAD1 PDLIM5 SLC6A3
2 drug binding GO:0008144 9.63 DRD3 HTR2A SLC6A3
3 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A3 SLC6A4
4 inositol monophosphate 3-phosphatase activity GO:0052832 9.4 IMPA1 IMPA2
5 inositol monophosphate phosphatase activity GO:0052834 9.37 IMPA1 IMPA2
6 inositol monophosphate 4-phosphatase activity GO:0052833 9.32 IMPA1 IMPA2
7 inositol monophosphate 1-phosphatase activity GO:0008934 9.26 IMPA1 IMPA2
8 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.16 TH TPH1
9 dopamine:sodium symporter activity GO:0005330 8.96 SLC6A3 SLC6A4
10 dopamine binding GO:0035240 8.8 DRD3 SLC6A3 TH

Sources for Bipolar Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA